Financial Times: U.S.-U.K. partnership to tackle antibiotic resistance
“A U.S.-U.K. public-private partnership will spend hundreds of millions of dollars over five years to tackle antibiotic resistance, a threat to public health worldwide. The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator or CARB-X brings together partners including the U.S. government’s Department of Health and Human Services, Wellcome Trust in London, AMR Centre in Alderley Park, Cheshire, and Boston University…” (Cookson, 7/28).

National Geographic: Millions Injected Into Push for New Antibiotics
“A new federal-private partnership will devote more than $350 million over the next five years to one of the trickiest aspects of the problem of drug resistance: encouraging pharmaceutical companies to make new antibiotics…” (McKenna, 7/28).

Reuters: U.S. and U.K. form global partnership to speed new antibiotics
“…The U.S. Department of Health and Human Services said on Thursday it would provide $30 million in the first year and up to $250 million during the five-year project. Britain’s AMR Centre, a public-private initiative, will contribute $14 million initially and up to $100 million over five years, while the London-based Wellcome Trust will supply further unspecified funding…” (Hirschler, 7/28).

Wall Street Journal: U.S. to Form International Partnership to Fight ‘Superbugs’
“…The venture, which has grown out of a 2015 Obama administration initiative, will focus on providing monetary help to small companies and laboratories that are in the earliest stages of developing new drugs, vaccines, or medical devices to combat such microbes…” (Burton, 7/28).

Washington Post: Major global partnership to speed antibiotic development launched
“…Biomedical innovations often take place in small companies and academic labs that don’t have the resources and expertise to move products to clinical development. CARB-X aims to provide necessary funding for research and development and technical assistance to move products from proof of concept through preclinical development…” (Sun, 7/28).